Cinctive Capital Management LP Invests $3.01 Million in Natera, Inc. $NTRA

Key Points

• Cinctive Capital Management LP has acquired a new stake in Natera, Inc., purchasing 21,295 shares valued at around $3 million.
• Natera's recent quarterly earnings report indicated a loss of $0.74 per share, missing the consensus estimate while achieving a 32.2% year-over-year revenue increase to $546.6 million.
• Several research analysts maintain an "overweight" rating on Natera, with price targets ranging from $183.00 to $220.00, reflecting positive sentiment despite recent challenges.

Cinctive Capital Management LP purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 21,295 shares of the medical research company's stock, valued at approximately $3,011,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in NTRA. Price T Rowe Associates Inc. MD raised its holdings in Natera by 56.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock valued at $1,490,144,000 after acquiring an additional 3,795,315 shares during the period. Nuveen LLC purchased a new stake in Natera during the first quarter valued at about $113,375,000. JPMorgan Chase & Co. boosted its holdings in shares of Natera by 9.9% during the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock worth $1,041,055,000 after purchasing an additional 660,538 shares during the period. SG Americas Securities LLC raised its stake in Natera by 8,233.5% in the first quarter. SG Americas Securities LLC now owns 397,924 shares of the medical research company's stock worth $56,270,000 after buying an additional 393,149 shares in the last quarter. Finally, Maverick Capital Ltd. increased its stake in shares of Natera by 19.7% during the first quarter. Maverick Capital Ltd. now owns 1,634,769 shares of the medical research company's stock valued at $231,173,000 after purchasing an additional 268,715 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Natera Trading Down 0.4%

NASDAQ NTRA traded down $0.63 during mid-day trading on Monday, hitting $167.39. The company's stock had a trading volume of 841,017 shares, compared to its average volume of 1,058,112. The stock's fifty day simple moving average is $154.32 and its two-hundred day simple moving average is $153.72. Natera, Inc. has a 52-week low of $114.62 and a 52-week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same period in the prior year, the firm earned ($0.30) EPS. The business's revenue for the quarter was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on NTRA shares. Barclays reissued an "overweight" rating and set a $210.00 price target (up previously from $190.00) on shares of Natera in a research report on Friday, August 8th. Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Piper Sandler reissued an "overweight" rating and issued a $220.00 price objective (up from $210.00) on shares of Natera in a research report on Monday, August 11th. Morgan Stanley reissued an "overweight" rating and set a $195.00 target price on shares of Natera in a research report on Sunday, August 10th. Finally, Cowen reiterated a "buy" rating on shares of Natera in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company. Based on data from MarketBeat.com, Natera currently has a consensus rating of "Buy" and a consensus price target of $194.00.

Insider Transactions at Natera

In other news, Director Rowan E. Chapman sold 2,750 shares of the company's stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total transaction of $459,222.50. Following the completion of the transaction, the director directly owned 6,015 shares in the company, valued at $1,004,444.85. The trade was a 31.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gail Boxer Marcus sold 2,496 shares of the company's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $133.17, for a total value of $332,392.32. Following the completion of the sale, the director owned 5,763 shares in the company, valued at $767,458.71. This trade represents a 30.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 60,423 shares of company stock worth $9,117,416. 5.63% of the stock is currently owned by company insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.